These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 39080372)

  • 1. Predictive value of inflammation and nutritional index in immunotherapy for stage IV non-small cell lung cancer and model construction.
    Lei W; Wang W; Qin S; Yao W
    Sci Rep; 2024 Jul; 14(1):17511. PubMed ID: 39080372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
    Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
    Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
    Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
    PeerJ; 2022; 10():e14566. PubMed ID: 36540802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
    Horstman IM; Vinke PC; Suazo-Zepeda E; Hiltermann TJN; Heuvelmans MA; Corpeleijn E; de Bock GH
    Thorac Cancer; 2024 Aug; 15(23):1764-1771. PubMed ID: 39030876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
    Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
    Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study.
    Zheng F; Meng Q; Zhang L; Chen J; Zhao L; Zhou Z; Liu Y
    World J Surg Oncol; 2023 Jul; 21(1):198. PubMed ID: 37420219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases.
    Asano Y; Hayashi K; Takeuchi A; Kato S; Miwa S; Taniguchi Y; Okuda M; Matsumoto I; Yano S; Demura S
    Int Immunopharmacol; 2024 Jul; 136():112276. PubMed ID: 38820958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 14. [Establishment and validation of a predictive nomogram model for advanced gastric cancer with perineural invasion].
    Liu SH; Hou XY; Zhang XX; Liu GW; Xin FJ; Wang JG; Zhang DL; Wang DS; Lu Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Nov; 23(11):1059-1066. PubMed ID: 33212554
    [No Abstract]   [Full Text] [Related]  

  • 15. The advanced lung cancer inflammation index (ALI) predicted the postoperative survival rate of patients with non-small cell lung cancer and the construction of a nomogram model.
    Ma S; Li Z; Wang L
    World J Surg Oncol; 2024 Jun; 22(1):158. PubMed ID: 38877553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
    Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
    JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
    Front Immunol; 2021; 12():724443. PubMed ID: 34777341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets.
    Liu A; Zhang G; Yang Y; Xia Y; Li W; Liu Y; Cui Q; Wang D; Yu J
    Cancer Immunol Immunother; 2024 Jun; 73(8):152. PubMed ID: 38833153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.